SAMPLE TO OUTCOME
LIVE

Serial Number

79264602

Owner

QIAGEN GMBH

Attorney

Keith A. Weltsch

Filing Date

May 21, 2019

Add to watchlist:

No watchlists yet
View on USPTO

SAMPLE TO OUTCOME Trademark

Serial Number: 79264602 • Registration: 6087728

SAMPLE TO OUTCOME is a trademark filed by QIAGEN GMBH on May 21, 2019. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

QIAGEN GMBH (212 trademarks)

HILDEN D-4010 , DE

Entity Type: 03

Trademark Details

Filing Date

May 21, 2019

Registration Date

June 30, 2020

Published for Opposition

April 14, 2020

Goods & Services

Downloadable and recorded computer software for data and document management, medical teaching; downloadable and recorded computer software and related databases for use in preparing and managing nucleic acid and protein assay analysis and for managing quality control, validation, interpretation, reporting, clinical decision support, data management, integration with medical records, physician portals, laboratory networking, professional healthcare and trial matching services all related to molecular and genomic analysis; downloadable and recorded computer software, namely, evidence-based decision support software used as an aid in the interpretation of variants observed in genomic sequencing data; downloadable and recorded computer software for evaluation of genomic variants in the context of software for searching and allocating published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and/or clinical-trials; downloadable and recorded computer software for preparing, interpretation and managing of bioinformatics analyses, optionally combined with data management, graphical viewing and output options; downloadable and recorded computer programs and software for biological data mining; downloadable and recorded computer programs and software for developing bioinformatics database for others; bio-chips for research or scientific purposes; DNA-chips; RNA-chips; next-generation sequencing (NGS) data processor; bioinformatics data processor; computer hardware and downloadable and recorded computer software for collecting, storing, analyzing, visualizing, and interpreting bioinformatics, genomics, and phenomics data sets; computer hardware and downloadable and recorded computer software for the monitoring of pathogens; downloadable computer databases for bioinformatics, genomics, phenomics, microbiome, metagenomics, organism-and -pathogen-specific genotype records, and organism and pathogen-specific phenotype information; downloadable and recorded computer software for use in the integration, analysis and visualization of biomedically relevant information allowing users to explore compound, target, assay, biological pathway and disease information; downloadable and recorded computer software and databases for the analysis of genomes, exomes, targeted amplicons, transcriptomes, and epigenetic NGS sequencing data; downloadable and recorded computer software, software development tools, and visualization software modules, for analysis, discovery, verification, and validation of disease biomarkers

Medical diagnostic testing instruments for processing and analysis of genetic samples primarily for single-cell genomic, transcriptomic, or proteomic analysis; medical and diagnostic apparatus for testing DNA and RNA samples, using gene expression tests, gene expression profiling assays, genetic information and data, protein biomarkers, clinical data, and/or demographic information; testing apparatus for medical purposes for testing DNA and RNA samples sold as a unit with downloadable bioinformatics and machine learning algorithm software and medical data software to support treatment decisions; medical testing apparatus for testing DNA and RNA samples and quantifying biomarker levels and relative expression of host response genes; medical apparatus and instruments for detecting tumor cancer, heredity and genetic diseases; medical testing apparatus for samples of body fluids, tissue and organs; genome machine for medical purposes, namely, apparatus for DNA and RNA medical testing; diagnostic apparatus for the detection of cancer, genetic or heredity diseases

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 30, 2025 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 10, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 24, 2020 FICS
FINAL DISPOSITION PROCESSED
Oct 23, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 30, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 30, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 14, 2020 NPUB
PUBLISHED FOR OPPOSITION
Apr 14, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 25, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 11, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 5, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2020 TROA
REFUSAL PROCESSED BY IB
Sep 20, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 4, 2019 RFCS
REFUSAL PROCESSED BY MPU
Sep 4, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 21, 2019 RFCR
NON-FINAL ACTION WRITTEN
Aug 20, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Aug 20, 2019 MAFR
ASSIGNED TO EXAMINER
Aug 16, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 8, 2019 REPR